Industry Liaison Forum

The ILF highlights the perspective of the HIV biomedical industry and catalyses multi-stakeholder dialogue and engagement as well as reflections and actions to address barriers along the HIV – prevention, diagnostics and treatment – cascade. Challenges around cross-cutting issues affecting industry’s contribution to the HIV response are also of central importance.

The ILF performs this role by bringing together stakeholders (e.g., through roundtable discussions) and by highlighting key data and points of view (e.g., with publications). The work of the ILF is guided by a strong, multi-stakeholder advisory group, which is composed of industry and non-industry representatives.

Learn more here.


Latest Publications



How to meet the first-ever global hepatitis targets

Blog post by Sébastien Morin, Eliot Ross Albers and Jürgen Rockstroh

HCV has historically been under-estimated, under-prioritized and under-resourced in comparison to the significant impact it has on millions of people around the world. However, with the adoption of the global hepatitis targets this is changing and an HCV-free generation, where the disease is no longer a great public health concern, is on the horizon.

Read the full post



ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Stimulating Development of the most needed formulations

The global community has identified priorities for future research and development for paediatric ARV formulations through the Paediatric ARV Drug Optimization (PADO) meetings; however, there are many challenges to making these formulations available. Although coordinated procurement efforts have been successful in reducing market fragmentation, the paediatric market is small compared with adults, and manufacturers do not have incentives to develop these priority paediatric formulations. Existing regulatory frameworks promote development of paediatric formulations, but implementation of those frameworks may have resulted in inefficient allocation of resources for paediatric research and development. In addition, the success in preventing mother-to-child transmission has reduced the number of new HIV infections, making it increasingly challenging to conduct robust clinical trial to assess efficacy, safety and acceptability of new paediatric drugs and fixed dose combinations across the age spectrum.

The ILF and CIPHER jointly held this technical meeting, which delivered information on the gaps between available and most needed paediatric ARV formulations and some existing innovative funding mechanisms and partnerships to support collaborative research and development between the public and private sectors. Creative solutions to alternative financing mechanisms, which build upon existing regulatory processes, to optimize the investment in paediatric ARVs, and enable a more sustainable development of prioritized products were discussed to ensure availability of the best treatment for infants and children living with HIV in the future.

Download the meeting report



Modern HIV prevention: what’s next for women?

Blog post by Lisa Levin, Cate Hankins, Brent Allan, Rahab Mwaniki, Nelli Bazarova, Sébastien Morin, and Linda-Gail Bekker

Today, some of the world’s leading scientists and researchers were gathered in Boston at the Conference on Retroviruses and Opportunistic Infections (CROI). “What’s next for women?” was the question on the minds of many, after results were released from two trials that looked at one of the most promising new HIV prevention tools of our time: the long-acting dapivirine vaginal ring, a female-controlled HIV prevention method that could potentially protect women for up to a month at a time.

Read the full post



ILF Annual Report 2015

In 2015, the ILF catalysed multi-stakeholder discussions in a diversity of fields aligned with IAS Member Priorities. In addition, the ILF Advisory Group continued to expand, and now includes a broader range of industry and non-industry participants from diverse sectors. These were the major ILF activities in 2015:

  • ILF Thematic Roundtable on Key Populations
  • ILF/CIPHER Thematic Roundtable on Paediatric ARVs: Aligning, Coordinating and Accelerating Actions to Provide Better ARVs for Children
  • ILF/CIPHER Thematic Roundtable on Paediatric HIV Diagnostics: Early Infant Diagnosis and Beyond
  • ILF/Co-Infections Thematic Roundtable on the Road to HCV Elimination
  • IAS-Industry Consultation on Integration of HIV and Other Diseases: From Single Disease to Complete Patient Management
  • ILF Advisory Group Meeting on Strategies for an Impactful ILF in 2016 and Beyond.

Download the annual report



ILF/CIPHER Thematic Roundtable on Paediatric HIV Diagnostics
From development to implementation, there are challenges in paediatric HIV diagnostics. The 2013 WHO guidelines recommended virological testing of infants at risk of perinatal and intra-partum HIV infection between four and six weeks of age. Moving forward, there are discussions around testing infants earlier and closer to the point of care to ensure that HIV-exposed infants are identified as early as possible, and can begin treatment as soon as possible because HIV-infected infants otherwise often die in the first months of life. This will also require expanding the testing net and integrating HIV testing in other health care platforms to identify children who are not picked up through the established prevention of mother-to-child transmission cascade. The ILF and CIPHER jointly held this technical meeting, which delivered information on the paediatric HIV diagnostics continuum, highlighting challenges and existing initiatives, alongside an overview of WHO guidance and guideline development. Creative solutions to overcome barriers of the development and the delivery of optimal paediatric HIV diagnostics were discussed.

Download the meeting report



Paediatric ARVs: Giving industry a seat at the table

Blog post by Marissa Vicari and Sébastien Morin from the IAS

There must be a partnership between business and the community - without that this battle will not be won.” – Nelson Mandela

In his closing address at the 2000 International AIDS Conference in Durban, South Africa, Nelson Mandela recognized the necessity of industry’s involvement in the HIV response -- even before generic antiretrovirals (ARVs) were made available at low cost to the world. At the time, the relationship between industry and civil society was characterized, at best, as tense... 

Read the full post



ILF/CIPHER Thematic Roundtable on Paediatric ARVs
Following the success of the roundtable series on paediatric HIV, a follow-up roundtable took place on 18 March 2015 in Geneva, Switzerland. This meeting, on the topic of “Aligning, coordinating and accelerating actions to provide better ARVs for children”, was an occasion to provide a forum to report back on the PADO 2 meeting, working up to the next WHO consolidated ARV guidelines revision, as well as to discuss the recent progresses in the paediatric ARV space and highlight some of the remaining challenges in that field.

Download the meeting report





ILF Corporate Partners




See the list of previous industry partners   |   Learn about the ILF Corporate Partnership Programme